Statin Landmark Trials Across the Spectrum of Risk:Secondary CV Prevention
Slide lecture program (17 slides): View & Download
- TNT: Study Design Treating to New Targets
- TNT Primary Efficacy Outcome Measure:Major Cardiovascular Events
- TNT: Primary and Secondary Efficacy Outcomes
- TNT: Time to First Fatal or Nonfatal Stroke
- TNT: Safety Profile
- IDEAL (Incremental Decrease in EndPoints Through Aggressive Lipid Lowering): Study Design
- IDEAL: Primary and Secondary End Points
- Effects of Atorvastatin 80 mg/d vs Simvastatin 20 to 40 mg/d on Any CV Event
- MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering): Study Design
- MIRACL: Primary Efficacy Measure—Time to First Event
- MIRACL: Stroke
- PROVE IT-TIMI (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction) 22: Study Design
- PROVE IT: Primary End Point (All-Cause Death or Major CV Events in All Randomized Subjects)
- PROVE IT-TIMI 22: Intensive Therapy With Statins in Patients With ACS: Early and Long-term Benefits
- Safety of Atorvastatin 80 mg in Clinical Trials
- Overview of Adverse Events forAtorvastatin 10 mg and 80 mg and Placebo
- TNT: Changes in LDL-C by Treatment
- PROVE IT: Reductions in Major Cardiac End Point
- Effect of Intensive Statin Therapy on Clinical Outcomes
- Long-term Statin Treatment in IDEAL Maintained Benefit Over 5 Years
- MIRACL: Secondary End Points
- Association of Dyslipidemia and myocardial Infarction Risk: INTERHEART
- ASCOT CRP Analysis
Click on slides to preview
Download slides below
Share this page with your colleagues and friends: